BioXcel Report Results of BXCL501 in P-Ib/II RELEASE Study for the Treatment of Opioid Withdrawal Symptoms

Shots:

• The P-Ib/II POC, RELEASE study involves assessing BXCL50 (130/ 60 /90 /120 /180 and 240 mcg, bid, ~ 12 hrs apart, 7 days treatment) vs PBO, following discontinuation of morphine maintenance in 125 patients with opioid use disorder who are physically dependent on opioids
• The study met its 1EPs and 2EPs in multiple dose cohort demonstrated numerically improvement in retention rates, rate of retention in 120mcg and 180mcg showed 42% and 52% vs 24% @Day 6 and was well tolerated
• The data from multiple dosing regimen has the potential to support the investigation across additional indications and treatment settings

Click here to­ read full press release/ article | Ref: GlobeNewswire | Image: Linkedin